MCID: PPL018
MIFTS: 46

Papillary Adenocarcinoma

Categories: Cancer diseases

Aliases & Classifications for Papillary Adenocarcinoma

MalaCards integrated aliases for Papillary Adenocarcinoma:

Name: Papillary Adenocarcinoma 12 14 69
Infiltrating and Papillary Adenocarcinoma 12
Infiltrating Papillary Adenocarcinoma 12
Papillary Adenocarcinoma Nos 12
Adenocarcinoma, Papillary 42
Adenocarcinoma Papillary 52

Classifications:



External Ids:

Disease Ontology 12 DOID:3112
MeSH 42 D000231
NCIt 47 C2853 C7438

Summaries for Papillary Adenocarcinoma

Disease Ontology : 12 An adenocarcinoma that derives from epithelial cells originating in glandular tissue, which form complex papillary structures and exhibit compressive, destructive growth that replaces the normal tissue.

MalaCards based summary : Papillary Adenocarcinoma, also known as infiltrating and papillary adenocarcinoma, is related to gastric papillary adenocarcinoma and eccrine papillary adenocarcinoma. An important gene associated with Papillary Adenocarcinoma is NKX2-1 (NK2 Homeobox 1), and among its related pathways/superpathways are Adhesion and Photodynamic therapy-induced NFE2L2 (NRF2) survival signaling. The drugs Sunitinib and Cisplatin have been mentioned in the context of this disorder. Affiliated tissues include thyroid, lung and cervix, and related phenotypes are Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance and cardiovascular system

Wikipedia : 72 Papillary adenocarcinoma is a histological form of lung cancer that is diagnosed when the malignant... more...

Related Diseases for Papillary Adenocarcinoma

Diseases related to Papillary Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 247)
id Related Disease Score Top Affiliating Genes
1 gastric papillary adenocarcinoma 34.0 CEACAM5 MUC1
2 eccrine papillary adenocarcinoma 32.7 KEAP1 NFE2L2
3 papilloma 30.6 MUC1 PGR
4 aggressive digital papillary adenocarcinoma 12.3
5 lung papillary adenocarcinoma 12.0
6 peritoneal serous papillary adenocarcinoma 12.0
7 fallopian tube papillary adenocarcinoma 11.8
8 nasopharyngeal carcinoma 3 10.9
9 papillary serous adenocarcinoma 10.9
10 2q31.1 microdeletion syndrome 10.9 MUC1 VIM
11 adenocarcinoma 10.8
12 myeloid/lymphoid neoplasm associated with pdgfra rearrangement 10.8 MUC1 VIM
13 spleen angiosarcoma 10.8 MUC1 VIM
14 myoma 10.8 MUC1 VIM
15 laryngeal neuroendocrine tumor 10.8 MUC1 VIM
16 noninvasive malignant thymoma 10.8 MUC1 VIM
17 reticular pattern testicular yolk sac tumor 10.8 MUC1 VIM
18 pancreatic intraductal papillary-colloid carcinoma 10.8 MUC1 VIM
19 lice infestation 10.8 MUC1 VIM
20 chronic neutrophilic leukemia 10.8 MUC1 NKX2-1
21 lymphangiosarcoma 10.8 MUC1 VIM
22 ganglioglioma 10.8 MUC1 VIM
23 anaplastic oligodendroglioma 10.8 MUC1 VIM
24 exotropia 10.8 MUC1 PGR
25 diffuse meningeal melanocytosis 10.8 MUC1 VIM
26 skin papilloma 10.7 NKX2-1 VIM
27 fallopian tube germ cell cancer 10.7 MUC1 VIM
28 lymphocytic infiltrate of jessner 10.7 PGR VIM
29 pleural empyema 10.7 MUC1 NKX2-1
30 ovary papillary carcinoma 10.7 MUC1 VIM
31 childhood pleomorphic rhabdomyosarcoma 10.7 MUC1 VIM
32 vulvar squamous papilloma 10.7 MUC1 VIM
33 spindle cell liposarcoma 10.7 MUC1 VIM
34 pineal region yolk sac tumor 10.7 PGR VIM
35 pancreatic serous cystadenoma 10.7 MUC1 VIM
36 subependymal glioma 10.7 MUC1 VIM
37 berk-tabatznik syndrome 10.7 PGR VIM
38 lung squamous cell carcinoma 10.7 CEACAM5 MUC1
39 short-rib thoracic dysplasia 12 10.7 MUC1 VIM
40 pseudounicornuate uterus 10.7 PGR VIM
41 coronary restenosis 10.7 MUC1 VIM
42 extraskeletal mesenchymal chondrosarcoma 10.7 MUC1 VIM
43 gastritis 10.7 ERBB2 PGR
44 breast pericanalicular fibroadenoma 10.7 NKX2-1 PGR
45 glaucoma, hereditary 10.7 ERBB2 PGR
46 ovary neuroendocrine neoplasm 10.7 MUC1 PGR
47 pancreatic ductal carcinoma 10.7 MUC1 VIM
48 her2-receptor negative breast cancer 10.7 ERBB2 PGR
49 spinal cancer 10.7 ERBB2 PGR
50 pulmonary venoocclusive disease 10.7 MUC1 VIM

Graphical network of the top 20 diseases related to Papillary Adenocarcinoma:



Diseases related to Papillary Adenocarcinoma

Symptoms & Phenotypes for Papillary Adenocarcinoma

GenomeRNAi Phenotypes related to Papillary Adenocarcinoma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 8.92 ERBB2 MST1R MUC1 VIM

MGI Mouse Phenotypes related to Papillary Adenocarcinoma:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.91 CDH1 ERBB2 MUC2 NFE2L2 NKX2-1 PGR
2 homeostasis/metabolism MP:0005376 9.91 NKX2-1 PGR VIM CDH1 ERBB2 KEAP1
3 mortality/aging MP:0010768 9.85 CDH1 ERBB2 FGF3 KEAP1 MST1R MUC2
4 digestive/alimentary MP:0005381 9.8 CDH1 ERBB2 KEAP1 MUC2 NFE2L2 NKX2-1
5 neoplasm MP:0002006 9.43 CDH1 ERBB2 MUC2 NFE2L2 NKX2-1 PGR
6 reproductive system MP:0005389 9.17 CDH1 ERBB2 FGF3 MST1R NKX2-1 PGR

Drugs & Therapeutics for Papillary Adenocarcinoma

Drugs for Papillary Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 157)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sunitinib Approved, Investigational Phase 3,Phase 2 341031-54-7, 557795-19-4 5329102
2
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
3
Doxorubicin Approved, Investigational Phase 3,Phase 2 23214-92-8 31703
4
Epirubicin Approved Phase 3 56420-45-2 41867
5
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
6
Paclitaxel Approved, Vet_approved Phase 3,Phase 1,Phase 2 33069-62-4 36314
7
Everolimus Approved Phase 2, Phase 3,Phase 1 159351-69-6 6442177
8
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3,Phase 1 22916-47-8 4189
9
Sirolimus Approved, Investigational Phase 2, Phase 3,Phase 1 53123-88-9 5284616 6436030 46835353
10
Capecitabine Approved, Investigational Phase 3 154361-50-9 60953
11
Fluorouracil Approved Phase 3 51-21-8 3385
12
Gemcitabine Approved Phase 3,Phase 2 95058-81-4 60750
13
Pancrelipase Approved Phase 3 53608-75-6
14
Letrozole Approved, Investigational Phase 2, Phase 3 112809-51-5 3902
15
Doxil Approved June 1999 Phase 3,Phase 2 31703
16 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1
17 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1
18 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
19 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
20 Topoisomerase Inhibitors Phase 3,Phase 2
21 Anti-Infective Agents Phase 3,Phase 2,Phase 1
22 Antimetabolites Phase 3,Phase 2
23 Antimetabolites, Antineoplastic Phase 3,Phase 2
24
Erlotinib Hydrochloride Phase 3,Phase 2 183319-69-9 176871
25 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
26 Protein Kinase Inhibitors Phase 3,Phase 1,Phase 2
27 Albumin-Bound Paclitaxel Phase 3,Phase 1,Phase 2
28 Antimitotic Agents Phase 3,Phase 1,Phase 2
29 Antineoplastic Agents, Phytogenic Phase 3,Phase 1,Phase 2
30 Antifungal Agents Phase 2, Phase 3,Phase 1
31 Hormone Antagonists Phase 2, Phase 3
32 Hormones Phase 2, Phase 3
33 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2, Phase 3
34 Antiviral Agents Phase 3,Phase 2
35 pancreatin Phase 3
36 Aromatase Inhibitors Phase 2, Phase 3
37 Estrogen Antagonists Phase 2, Phase 3
38 Estrogens Phase 2, Phase 3
39 Steroid Synthesis Inhibitors Phase 2, Phase 3
40
Bevacizumab Approved, Investigational Phase 2 216974-75-3
41
Azacitidine Approved, Investigational Phase 2 320-67-2 9444
42
Decitabine Approved, Investigational Phase 2 2353-33-5 451668
43
Salmon Calcitonin Approved, Investigational Phase 2 47931-85-1 16129616
44
Romidepsin Approved, Investigational Phase 2 128517-07-7 5352062
45
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
46
Cimetidine Approved Phase 2 51481-61-9 2756
47
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
48
Diphenhydramine Approved Phase 2 58-73-1, 147-24-0 3100
49
Histamine Approved, Investigational Phase 2 75614-87-8, 51-45-6 774
50
Promethazine Approved Phase 2 60-87-7 4927

Interventional clinical trials:

(show top 50) (show all 79)

id Name Status NCT ID Phase Drugs
1 Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Endometrial Cancer Completed NCT00005583 Phase 3 cisplatin;doxorubicin hydrochloride;epirubicin hydrochloride
2 Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery Recruiting NCT01013649 Phase 3 Capecitabine;Chemotherapy;Erlotinib Hydrochloride;Fluorouracil;Gemcitabine Hydrochloride
3 Savolitinib vs. Sunitinib in MET-driven PRCC Recruiting NCT03091192 Phase 3 Savolitinib;Sunitinib
4 Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer Active, not recruiting NCT00807768 Phase 3 Carboplatin;Paclitaxel
5 Treatment Plan for an Individual Patient With Recurrent Uterine Papillary Serous Carcinoma (UPSC) With PIK3CA Gene Mutation Active, not recruiting NCT03285802 Phase 2, Phase 3 Letrozole;Everolimus
6 Sunitinib as First-Line Therapy in Treating Patients With Locally Advanced Metastatic Papillary Renal Cell Cancer Unknown status NCT00541008 Phase 2 sunitinib malate
7 Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer Completed NCT01010126 Phase 2 Temsirolimus
8 RAPTOR: RAD001 as Monotherapy in the Treatment of Advanced Papillary Renal Cell Tumors Program in Europe Completed NCT00688753 Phase 2 RAD001
9 Decitabine in Treating Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Iodine I 131 Completed NCT00085293 Phase 2 Decitabine
10 Romidepsin in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Has Not Responded to Radioactive Iodine Completed NCT00098813 Phase 2 romidepsin
11 Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy Completed NCT00104871 Phase 2 Bortezomib
12 Sutent Adjunctive Treatment of Differentiated Thyroid Cancer Completed NCT00668811 Phase 2 SU011248, Sutent
13 Gleevec/Taxol for Patients With Uterine Papillary Serous Carcinoma Completed NCT00506779 Phase 1, Phase 2 Imatinib Mesylate;Paclitaxel
14 A Phase II Study of GSK1363089 (Formerly XL880) for Papillary Renal-Cell Carcinoma (PRC) Completed NCT00726323 Phase 2 foretinib (formerly GSK1363089 or XL880)
15 Erlotinib in Treating Patients With Locally Advanced or Metastatic Papillary Renal Cell Cancer Completed NCT00060307 Phase 2 erlotinib hydrochloride
16 Papillary Serous Carcinoma of the Endometrium Completed NCT00515073 Phase 2 Paclitaxel;Dexamethasone;Cimetidine;Diphenhydramine
17 A Study of Radiation Therapy and Paclitaxel and Carboplatin in Patients With Uterine Papillary Serous Carcinoma Completed NCT00231868 Phase 2 Carboplatin and Paclitaxel and Pelvic Radiation Therapy;Carboplatin and Paclitaxel and Radiation Therapy
18 Aflibercept in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy Completed NCT00729157 Phase 2
19 Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer Completed NCT01502410 Phase 2 sorafenib tosylate
20 Thalidomide in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT00025467 Phase 2 thalidomide
21 Tivantinib With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Locally Advanced Kidney Cancer That Cannot Be Removed by Surgery Completed NCT01688973 Phase 2 Erlotinib Hydrochloride;Tivantinib
22 Tanespimycin in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer Completed NCT00118248 Phase 2 tanespimycin
23 Sunitinib in Treating Patients With Locally Recurrent or Metastatic Kidney Cancer Completed NCT00459875 Phase 2 sunitinib malate
24 Intensity-Modulated Radiation Therapy, Cisplatin, and Bevacizumab Followed by Carboplatin and Paclitaxel in Treating Patients Who Have Undergone Surgery for Endometrial Cancer Completed NCT01005329 Phase 2 cisplatin;carboplatin;paclitaxel
25 Temsirolimus in Treating Patients With Metastatic or Locally Advanced Recurrent Endometrial Cancer Completed NCT00072176 Phase 2 temsirolimus
26 Sunitinib Malate in Treating Patients With Iodine-Refractory Recurrent or Metastatic Thyroid Cancer Completed NCT00519896 Phase 2 sunitinib malate
27 RAMSETE: RAD001 in Advanced and Metastatic Silent Neuro-endocrine Tumors in Europe Completed NCT00688623 Phase 2 Everolimus
28 A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H... Completed NCT00923481 Phase 2 Fostamatinib disodium
29 Suberoylanilide Hydroxamic Acid in Treating Patients With Metastatic and/or Locally Advanced or Locally Recurrent Thyroid Cancer Completed NCT00134043 Phase 2 vorinostat
30 pazopanib_NCRCC,Ph2 STUDY Completed NCT01538238 Phase 2 pazopanib
31 Study to Evaluate Safety and Biological Activity of TroVax® Vaccine Given in Conjunction With IL-2 to Treat Locally Advanced or Metastatic Renal Cell Carcinoma Completed NCT00325507 Phase 2
32 Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers Recruiting NCT02978625 Phase 2
33 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
34 Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Recruiting NCT02101775 Phase 2 Gemcitabine Hydrochloride;WEE1 Inhibitor AZD1775
35 MEDI4736 Combinations in Metastatic Renal Cell Carcinoma Recruiting NCT02819596 Phase 2 Savolitinib;MEDI4736;Tremelimumab
36 A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer Recruiting NCT01130519 Phase 2 Bevacizumab;Erlotinib
37 A Phase 2 Study of the MET Kinase Inhibitor INC280 in Papillary Renal Cell Cancer Recruiting NCT02019693 Phase 2 INC280
38 Axitinib in1st Line Treatment for Patients With Advanced or Metastatic Papillary Renal Cell Carcinoma Recruiting NCT02489695 Phase 2 axitinib
39 Vandetanib in Combination With Metformin in People With HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell Carcinoma Recruiting NCT02495103 Phase 1, Phase 2 Vandetanib;Metformin
40 Cabozantinib-S-Malate, Crizotinib, Volitinib, or Sunitinib Malate in Treating Patients With Locally Advanced or Metastatic Kidney Cancer Recruiting NCT02761057 Phase 2 Cabozantinib S-malate;Crizotinib;Sunitinib Malate;Volitinib
41 Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer Recruiting NCT02393690 Phase 2 Selumetinib
42 Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer Recruiting NCT02152995 Phase 2 Trametinib
43 Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer Active, not recruiting NCT01116648 Phase 1, Phase 2 Cediranib Maleate;Olaparib
44 Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer Active, not recruiting NCT02283658 Phase 2 Everolimus;Letrozole
45 REVLIMID® (Lenalidomide) for Therapy of Radioiodine-Unresponsive Papillary and Follicular Thyroid Carcinomas Active, not recruiting NCT00287287 Phase 2 Lenalidomide
46 Fludeoxyglucose F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer Active, not recruiting NCT00416455 Phase 1, Phase 2 ferumoxtran-10
47 A Phase II Trial to Evaluate the Efficacy of AZD6094 (HMPL-504) in Patients With Papillary Renal Cell Carcinoma (PRCC) Active, not recruiting NCT02127710 Phase 2 AZD6094
48 Dabrafenib With or Without Trametinib in Treating Patients With Recurrent Thyroid Cancer Active, not recruiting NCT01723202 Phase 2 dabrafenib;trametinib
49 Cediranib Maleate With or Without Lenalidomide in Treating Patients With Thyroid Cancer Active, not recruiting NCT01208051 Phase 1, Phase 2 Cediranib Maleate;Lenalidomide
50 Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer Active, not recruiting NCT01811212 Phase 2 Cabozantinib S-malate

Search NIH Clinical Center for Papillary Adenocarcinoma

Cochrane evidence based reviews: adenocarcinoma, papillary

Genetic Tests for Papillary Adenocarcinoma

Anatomical Context for Papillary Adenocarcinoma

MalaCards organs/tissues related to Papillary Adenocarcinoma:

39
Thyroid, Lung, Cervix, Kidney, Liver, Lymph Node, Ovary

Publications for Papillary Adenocarcinoma

Articles related to Papillary Adenocarcinoma:

(show top 50) (show all 354)
id Title Authors Year
1
Endoscopic submucosal dissection for papillary adenocarcinoma of the stomach: is it really safe? ( 28271420 )
2017
2
Thyroid-like low-grade nasopharyngeal papillary adenocarcinoma with squamous differentiation: A novel histological finding. ( 28601658 )
2017
3
Cronkhite-Canada Syndrome with a Major Duodenal Papillary Adenocarcinoma. ( 28924129 )
2017
4
Cutaneous papillary adenocarcinoma in situ. ( 28164358 )
2017
5
Aggressive Digital Papillary Adenocarcinoma of the Hand Presenting as a Felon. ( 28421154 )
2017
6
Mohs Micrographic Surgery as a Digit-Sparing Treatment for Aggressive Digital Papillary Adenocarcinoma. ( 28291063 )
2017
7
Aggressive digital papillary adenocarcinoma: A clinicopathological study of 19 cases. ( 28495496 )
2017
8
Masson's Tumor Masquerading as a Papillary Adenocarcinoma on Fine Needle Aspiration Cytology: A Case Report. ( 28272657 )
2017
9
Aggressive digital papillary adenocarcinoma: treatment with Mohs micrographic surgery and an update of the literature. ( 28832985 )
2017
10
Response to: Cutaneous papillary adenocarcinoma in situ. ( 28299799 )
2017
11
Clinicopathological and molecular stability and methylation analyses of gastric papillary adenocarcinoma. ( 28830689 )
2017
12
Primary papillary adenocarcinoma of the lung: Report of two cases. ( 28474664 )
2017
13
Villoglandular papillary adenocarcinoma: case report. ( 28293348 )
2016
14
Villoglandular papillary adenocarcinoma of the uterine cervix: A report of 4 cases and a review of the literature. ( 26870293 )
2016
15
Aggressive Digital Papillary Adenocarcinoma With Multiple Organ Metastases: A Case Report and Review of the Literature. ( 27870729 )
2016
16
Malignant transformation of alveolar adenoma to papillary adenocarcinoma: a case report. ( 27162700 )
2016
17
An unexpected digital papillary adenocarcinoma of the thumb. ( 27990456 )
2016
18
Aggressive papillary adenocarcinoma on atypical localization: A unique case report. ( 27428196 )
2016
19
Papillary adnexal neoplasm (Aggressive digital papillary adenocarcinoma) on the ankle of a 15 year old girl: case report and review of literature from a pediatric perspective. ( 27535353 )
2016
20
Role of Radiotherapy in Aggressive Digital Papillary Adenocarcinoma. ( 27098633 )
2016
21
Treatment of endolymphatic sac tumour (Papillary adenocarcinoma) of the temporal bone. ( 27330425 )
2016
22
Thyroid-like low-grade nasopharyngeal papillary adenocarcinoma: A case report. ( 28105348 )
2016
23
A retrospective review of 11 cases of villoglandular papillary adenocarcinoma of the uterine cervix and a review of the literature. ( 26998142 )
2016
24
Low-grade papillary adenocarcinoma of nasopharynx with expression of thyroid transcription factor-1: Case report and review of literature. ( 27721286 )
2016
25
Papillary adenocarcinoma with tentacular processes (with video). ( 27302875 )
2016
26
Low-grade nasopharyngeal papillary adenocarcinoma: a case report and review of the literature. ( 27274289 )
2016
27
Clinicopathological Features of Low-Grade Thyroid-Like Nasopharyngeal Papillary Adenocarcinoma. ( 27384157 )
2016
28
Metastatic Papillary Adenocarcinoma in a 22-Year-Old: Is Her History of Mayer-Rokitansky-KA1ster-Hauser Syndrome Causative or Incidental? ( 27987200 )
2016
29
Papillary adenocarcinoma of the renal pelvis with renal calculus: A rare case report. ( 27123287 )
2016
30
Spreading Patterns, Prognostic factors and Treatment Outcomes of Nasopharyngeal Papillary Adenocarcinoma and Salivary Gland-type Carcinomas. ( 26118586 )
2015
31
Primary thyroid-like papillary adenocarcinoma of the nasal septum: a case report. ( 25651353 )
2015
32
Aggressive digital papillary adenocarcinoma - a rare malignant tumor of the sweat glands: two case reports and a review of the literature. ( 25848311 )
2015
33
Right visual loss due to choroidal metastasis of a papillary adenocarcinoma of the lung: a case report. ( 26662155 )
2015
34
Low-grade papillary adenocarcinoma of minor salivary glands in pregnancy. ( 26960505 )
2015
35
Aggressive Digital Papillary Adenocarcinoma: Case Report of a Positive Sentinel Lymph Node and Discussion of Utility of Sentinel Lymph Node Biopsy. ( 25954845 )
2015
36
Digital Papillary Adenocarcinoma: Presentation, Natural History and Management. ( 26266016 )
2015
37
Next-generation sequencing reveals rare genomic alterations in aggressive digital papillary adenocarcinoma. ( 26386519 )
2015
38
"Apocrine Hidrocystoma and Cystadenoma"-like Tumor of the Digits or Toes: A Potential Diagnostic Pitfall of Digital Papillary Adenocarcinoma. ( 26523544 )
2015
39
Aggressive Digital Papillary Adenocarcinoma. ( 26576210 )
2015
40
Is endoscopic submucosal dissection safe for papillary adenocarcinoma of the stomach? ( 25852280 )
2015
41
Endoscopic ultrasonography-guided drainage of infected intracystic papillary adenocarcinoma of the liver. ( 26412329 )
2015
42
Intraductal dissemination of papillary adenocarcinoma of the ampulla of Vater in the pancreatic duct. ( 24471969 )
2014
43
Primary serous papillary adenocarcinoma of the fallopian tube. ( 25163242 )
2014
44
Papillary adenocarcinoma in situ of the skin: report of four cases. ( 24855569 )
2014
45
Lung papillary adenocarcinoma complicated with paraneoplastic autoimmune hemolytic anemia: A case report. ( 26766978 )
2014
46
Aggressive Digital Papillary Adenocarcinoma-A rare Entity Posing a Diagnostic Challenge. ( 25977623 )
2014
47
Magnetic Resonance Manifestations of Villoglandular Papillary Adenocarcinoma of the Uterine Cervix with a Fern-leaf-like Appearance. ( 24990463 )
2014
48
Clinical significance of a papillary adenocarcinoma component in early gastric cancer: a single-center retrospective analysis of 628 surgically resected early gastric cancers. ( 25142800 )
2014
49
A rare coexistence of villoglandular papillary adenocarcinoma of the uterine cervix and brenner tumor of the ovary. ( 24716032 )
2014
50
Clinicopathological features of gallbladder papillary adenocarcinoma. ( 25501049 )
2014

Variations for Papillary Adenocarcinoma

Expression for Papillary Adenocarcinoma

Search GEO for disease gene expression data for Papillary Adenocarcinoma.

Pathways for Papillary Adenocarcinoma

Pathways related to Papillary Adenocarcinoma according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1 11.17 CDH1 CEACAM5 MUC1
2 10.7 KEAP1 NFE2L2
3 10.51 CDH1 VIM
4 10.33 KEAP1 NFE2L2
5 10.29 CDH1 ERBB2 MST1R

GO Terms for Papillary Adenocarcinoma

Biological processes related to Papillary Adenocarcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.46 ERBB2 NFE2L2 NKX2-1 VIM
2 peptidyl-tyrosine phosphorylation GO:0018108 9.43 ERBB2 FGF3 MST1R
3 oligodendrocyte differentiation GO:0048709 9.37 ERBB2 NKX2-1
4 pituitary gland development GO:0021983 9.32 CDH1 NKX2-1
5 positive regulation of transcription from RNA polymerase II promoter in response to stress GO:0036003 8.96 MUC1 NFE2L2
6 proteasomal ubiquitin-independent protein catabolic process GO:0010499 8.62 KEAP1 NFE2L2

Molecular functions related to Papillary Adenocarcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein tyrosine kinase activity GO:0004713 8.8 ERBB2 FGF3 MST1R

Sources for Papillary Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....